Health Canada approved Pediapharm Inc.'s Otixal for the treatment of acute otitis media with tympanostomy tubes in pediatric patients.
Otixal is an antibiotic and steroid combination ear drop.
Discover more about S&P Global’s offerings
Health Canada approves Pediapharm ear infection drug
Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost
Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion
Global M&A by the Numbers: Q2 2022
Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms
Health Canada approved Pediapharm Inc.'s Otixal for the treatment of acute otitis media with tympanostomy tubes in pediatric patients.
Otixal is an antibiotic and steroid combination ear drop.